CHRS | Jotup

Coherus Management to Present at the 2024 Jefferies Global Healthcare Conference

Retrieved on:

Giovedì, Maggio 30, 2024

REDWOOD CITY, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS) today announced that senior management will present at the 2024 Jefferies Global Healthcare Conference on Thursday, June 6, 2024 at 8:30 a.m. Eastern Daylight Time / 5:30 a.m. Pacific Daylight Time.

Key Points:

REDWOOD CITY, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS) today announced that senior management will present at the 2024 Jefferies Global Healthcare Conference on Thursday, June 6, 2024 at 8:30 a.m. Eastern Daylight Time / 5:30 a.m. Pacific Daylight Time.
The presentation will be accessible via Webcast through a link on the Investor Events and Presentations section of the Coherus website: https://investors.coherus.com/events-presentations.
This webcast will be available for replay until July 7, 2024.

Coherus Presents Preliminary Results from Phase I Dose Escalation Study of its Anti-chemokine receptor 8 (CCR8) Antibody, CHS-114, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Retrieved on:

Giovedì, Maggio 23, 2024

REDWOOD CITY, Calif., May 23, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS), today announced clinical data from the CHS-114, single agent dose escalation stage of its Phase 1 study at the ASCO Annual Meeting, taking place May 31 to June 4, 2024, at McCormick Place in Chicago. CHS-114 is a novel afucosylated human immunoglobulin G1 (IgG1) monoclonal antibody (mAb) that selectively and potently targets human CCR8 with no off-target binding. CCR8 is a G protein-coupled receptor (GPCR) that shows preferential expression on tumor resident Treg cells and has promise as a drug target for selectively targeting immune suppression in the tumor microenvironment (TME) without broadly depleting Treg cells, which has the known unwanted side effect of autoimmune activation.

Key Points:

“The Phase 1 preliminary dose escalation results are an important milestone as we progress our innovative I-O pipeline.
Abstract # 2664: Preliminary Results of a Phase 1, First-in-human, Dose Escalation Study of the Anti-CCR8 Cytolytic Antibody, CHS-114 (formerly SRF114) in Patients with Advanced Solid Tumors.
Preliminary results and acceptable safety profile support further evaluation of CHS-114 in combination treatment with toripalimab and other I-O agents.
In 19 patients evaluable for response, no objective responses were yet noted, while the stable disease rate was 47%.

Coherus Management to Present at the TD Cowen 5th Annual Oncology Innovation Virtual Summit: Insights for ASCO & EHA

Retrieved on:

Giovedì, Maggio 23, 2024

CHRS, EHA, ASCO

REDWOOD CITY, Calif., May 23, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS) today announced that senior management will present at the upcoming TD Cowen 5th Annual Oncology Innovation Virtual Summit: Insights for ASCO & EHA on Wednesday, May 29, 2024 at 12:00 p.m. Eastern Daylight Time / 9:00 a.m. Pacific Daylight Time.

Key Points:

REDWOOD CITY, Calif., May 23, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS) today announced that senior management will present at the upcoming TD Cowen 5th Annual Oncology Innovation Virtual Summit: Insights for ASCO & EHA on Wednesday, May 29, 2024 at 12:00 p.m. Eastern Daylight Time / 9:00 a.m. Pacific Daylight Time.
The presentation will be accessible via Webcast through a link on the Investor Events and Presentations section of the Coherus website: https://investors.coherus.com/events-presentations.
This webcast will be available for replay until June 26, 2024.

Coherus BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update

Retrieved on:

Giovedì, Maggio 9, 2024

REDWOOD CITY, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS), today reported financial results for the quarter ended March 31, 2024 and recent business highlights:

Key Points:

Total unit demand grew 36% in Q1 2024 compared to Q4 2023 and represented a 108% increase compared to Q1 2023.
Based on data from IQVIA, UDENYCA franchise market share for Q1 2024 was 25%, an increase of 10 market share points in Q1 2024 compared to Q4 2023.
LOQTORZI, the first and only FDA-approved treatment for recurrent, locally advanced or metastatic NPC, commercially launched on January 2, 2024.
Coherus projects combined R&D and SG&A expenses for 2024 to be in the range of $250 to $265 million.

Coherus Announces Full Repayment of Pharmakon Advisors $75 Million Term Loan

Retrieved on:

Giovedì, Maggio 9, 2024

Development, CHRS, Latham & Watkins, Barings LLC, Security (finance)

REDWOOD CITY, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS), today announced it entered into a combined term loan and product royalty financing agreement with Barings that has allowed Coherus to fully pay off the remaining $75 million of its Pharmakon Advisors term loan. This further reduces the Company’s term loan debt by approximately half, with an extended loan maturity date of May 2029.

Key Points:

REDWOOD CITY, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS), today announced it entered into a combined term loan and product royalty financing agreement with Barings that has allowed Coherus to fully pay off the remaining $75 million of its Pharmakon Advisors term loan.
This further reduces the Company’s term loan debt by approximately half, with an extended loan maturity date of May 2029.
“This debt and royalty financing arrangement fully repays the $75 million remaining on our prior $250 million term loan that was due in October 2025,” said Denny Lanfear, Chief Executive Officer of Coherus.
Under the term loan, Coherus received $38.7 million in proceeds from a structured debt loan with a May 2029 maturity.

Coherus Announces Clinical Collaboration with the Cancer Research Institute for a Novel Combination Evaluating LOQTORZI® (toripalimab-tpzi) with ENB Therapeutics' ENB-003 for the Treatment of Ovarian Cancer

Retrieved on:

Mercoledì, Maggio 8, 2024

Endothelin B receptor is implicated in tumorigenesis and tumor immune suppression for several solid tumors, including melanoma, ovarian, and pancreatic cancers.

Key Points:

Endothelin B receptor is implicated in tumorigenesis and tumor immune suppression for several solid tumors, including melanoma, ovarian, and pancreatic cancers.
Dr. Stagg continued, “The iPROC study DSC brings together a group of scientific experts within the CRI community to select promising combinations and rapidly advance them to clinical trials.
Importantly, the DSC is not confined by a pipeline but looks to work with companies with drugs that have a strong data package.
For this multiparty platform study to succeed, it requires science-driven, highly collaborative, and engaged companies.

Coherus Announces Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Retrieved on:

Mercoledì, Aprile 24, 2024

CHRS, Patient, McCormick Place

REDWOOD CITY, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS) today announced the first presentation of clinical data for CHS-114, a highly selective cytolytic anti-CCR8 antibody, at the upcoming ASCO Annual Meeting, which will be held from May 31 to June 4, 2024, at McCormick Place in Chicago.

Key Points:

REDWOOD CITY, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS) today announced the first presentation of clinical data for CHS-114, a highly selective cytolytic anti-CCR8 antibody, at the upcoming ASCO Annual Meeting, which will be held from May 31 to June 4, 2024, at McCormick Place in Chicago.
Title: Preliminary Results of a Phase 1, First-in-human, Dose Escalation Study of the Anti-CCR8 Cytolytic Antibody, CHS-114 (formerly SRF114) in Patients with Advanced Solid Tumors.

Coherus Presents Preclinical Data for CHS-1000, a Novel Anti-ILT4 Antibody, at the 2024 AACR Annual Meeting

Retrieved on:

Lunedì, Aprile 8, 2024

B cell, Ligand, Patient, CHRS, Tumor microenvironment, LILRB2, Cancer, Macrophage, PD-1, Neonatal Fc receptor, IND, Phenotype, Neoplasm, Poster, ILT4, Vaccine

REDWOOD CITY, Calif., April 08, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS), today presented preclinical data for its immuno-oncology pipeline candidate, CHS-1000, a novel ILT4 monoclonal antibody, at the 2024 AACR Annual Meeting being held in San Diego, California. Data presented show CHS-1000 is a potent monoclonal antibody that binds selectively to human ILT4 (also known as LILRB2) with high affinity, efficiently blocking interaction with its ligands and reversing immunosuppressive functions, leading to activation of human dendritic cells and T cells and promoting polarization of macrophages to an inflammatory M1 phenotype.

Key Points:

“Myeloid cell-mediated immunosuppression in the tumor microenvironment is a major contributor to tumor immune invasion and PD-1 resistance.
The data presented in this poster demonstrate the potential for CHS-1000 to reverse myeloid suppression and activate an inflammatory immune response.
“CHS-1000 is our first internally discovered development candidate, and we are excited to be filing the IND this quarter.
ILT4 and CD163, a marker of suppressive (M2) macrophages, are highly expressed in a broad range of solid tumors.

Coherus BioSciences Reports Fourth Quarter, Full Year 2023 Financial Results and Provides Current Business Update

Retrieved on:

Mercoledì, Marzo 13, 2024

UDENYCA net product sales increased 10% in the fourth quarter 2023 to $36.2 million compared to $33.0 million in the third quarter.

Key Points:

UDENYCA net product sales increased 10% in the fourth quarter 2023 to $36.2 million compared to $33.0 million in the third quarter.
Since commercial launch in May 2023, more than 727 accounts have ordered the Autoinjector presentation.
“Throughout 2023, Coherus demonstrated significant progress in transforming the Company’s business model and product portfolio for long-term sustainable growth,” said Denny Lanfear, Coherus’ Chairman and Chief Executive Officer.
Coherus is introducing a guidance range of combined 2024 R&D and SG&A expenses from $250 to $265 million.

Coherus to Report Fourth Quarter and Full Year 2023 Financial Results on March 13, 2024

Retrieved on:

Martedì, Marzo 5, 2024

PIN, Webcast, CHRS, Online shopping

REDWOOD CITY, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that its fourth quarter and full year 2023 financial results will be released after market close on Wednesday, March 13, 2024.

Key Points:

REDWOOD CITY, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that its fourth quarter and full year 2023 financial results will be released after market close on Wednesday, March 13, 2024.
Starting at 5:00 pm ET on March 13, 2024, Coherus’ management team will host a conference call and webcast to discuss financial results and provide a general business update.
A replay of the webcast will be available on http://investors.coherus.com following the conclusion of the live conference call.
A live and archived webcast will be available on the “Investors” section of the Coherus website at https://investors.coherus.com/events-presentations.